

# Monica A Slavin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435800/publications.pdf>

Version: 2024-02-01

279  
papers

14,026  
citations

27035

58  
h-index

30277

107  
g-index

285  
all docs

285  
docs citations

285  
times ranked

12193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus <sc>DNAemia</sc> and disease: current era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. Internal Medicine Journal, 2022, 52, 1759-1767.	0.5	6
2	Cost effectiveness of home based care of febrile neutropenia in children with cancer. Pediatric Blood and Cancer, 2022, 69, e29469.	0.8	8
3	Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. Journal of Antimicrobial Chemotherapy, 2022, 77, 1508-1524.	1.3	7
4	Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, , 1-3.	0.6	2
5	Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia. Clinical and Translational Immunology, 2022, 11, .	1.7	5
6	Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. Transplantation and Cellular Therapy, 2022, 28, 511.e1-511.e10.	0.6	5
7	[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematology, the, 2022, 9, e573-e584.	2.2	15
8	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. Clinical Infectious Diseases, 2021, 73, 487-496.	2.9	74
9	The role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG) Tj ETQq1 1 0.784314 rgBT /Over with acute leukemia prior to allogeneic hematopoietic cell transplant. Transplant Infectious Disease, 2021, 23, e13547.	0.7	10
10	Home-based care of low-risk febrile neutropenia in children an implementation study in a tertiary paediatric hospital. Supportive Care in Cancer, 2021, 29, 1609-1617.	1.0	20
11	Very late onset cytomegalovirus disease with ganciclovir resistance >15 years following renal transplantation. Transplant Infectious Disease, 2021, 23, e13441.	0.7	5
12	Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses, 2021, 64, 257-263.	1.8	23
13	CAR-T cell therapy and infection: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 749-758.	2.0	47
14	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2021, 27, 201-211.	0.6	23
15	Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients the role of therapeutic drug monitoring. Expert Review of Anti-Infective Therapy, 2021, 19, 707-718.	2.0	11
16	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study. Mycoses, 2021, 64, 30-34.	1.8	5
17	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease, 2021, 23, e13548.	0.7	7
18	Quality of inpatient antimicrobial use in hematology and oncology patients. Infection Control and Hospital Epidemiology, 2021, 42, 1235-1244.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Managing low-risk febrile neutropenia in children in the time of COVID-19: What matters to parents and clinicians. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 826-834.	0.4	7
20	Aspergillus Polymerase Chain Reaction—An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, S95-S101.	2.9	17
21	The impact of pharmacist-led antifungal stewardship interventions in the hospital setting: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 90-105.	0.5	1
22	Scedosporium and Lomentospora infections in lung transplant recipients. <i>Current Fungal Infection Reports</i> , 2021, 15, 49-66.	0.9	1
23	The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2010-2015.e4.	2.0	26
24	Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia. <i>Frontiers in Immunology</i> , 2021, 12, 641879.	2.2	8
25	Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 297-306.	1.3	11
26	Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016. <i>Vaccine</i> , 2021, 39, 3270-3278.	1.7	7
27	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 444-450.e3.	0.2	17
28	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
29	Severe case of Lemierre syndrome with multiple neurological and ophthalmological sequelae. <i>BMJ Case Reports</i> , 2021, 14, e244669.	0.2	2
30	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29275.	0.8	10
31	Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents. <i>EClinicalMedicine</i> , 2021, 40, 101095.	3.2	10
32	Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. <i>Blood Reviews</i> , 2021, 49, 100810.	2.8	15
33	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15
34	Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 798.e1-798.e10.	0.6	13
35	Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13719.	0.7	3
36	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3020-3028.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1235.	1.7	3
38	Antimicrobial stewardship in Australia: the role of qualitative research in programme development. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab166.	0.9	8
39	The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3847-3849.	2.0	9
40	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 37-66.	0.5	24
41	Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 18-36.	0.5	15
42	Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 89-117.	0.5	21
43	Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 118-142.	0.5	19
44	Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 143-176.	0.5	51
45	Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than <i>Aspergillus</i> in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 177-219.	0.5	25
46	Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 220-233.	0.5	6
47	Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 3-17.	0.5	9
48	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
49	Invasive pulmonary aspergillosis in critically ill patients with COVID-19 in Australia: implications for screening and treatment. <i>Internal Medicine Journal</i> , 2021, 51, 2129-2132.	0.5	5
50	Multilocus Sequence Typing Reveals Extensive Genetic Diversity of the Emerging Fungal Pathogen <i>Scedosporium aurantiacum</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 761596.	1.8	4
51	SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab502.	0.4	2
52	New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2020, 50, 277-284.	0.5	12
53	Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. <i>EClinicalMedicine</i> , 2020, 18, 100220.	3.2	34
54	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429

#	ARTICLE	IF	CITATIONS
55	The democratization of de-labeling: a review of direct oral challenge in adults with low-risk penicillin allergy. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1143-1153.	2.0	16
56	The QuantiFERON Monitor <sup>®</sup> assay is predictive of infection post allogeneic hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13260.	0.7	10
57	A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e4269-e4277.	2.9	11
58	Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns. <i>Leukemia and Lymphoma</i> , 2020, 61, 2292-2294.	0.6	5
59	Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. <i>EClinicalMedicine</i> , 2020, 23, 100394.	3.2	28
60	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope <sup>™</sup> Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	1.7	20
61	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
62	Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. <i>BMC Infectious Diseases</i> , 2020, 20, 228.	1.3	16
63	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope <sup>™</sup> registry. <i>Mycoses</i> , 2020, 63, 437-442.	1.8	41
64	Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. <i>Reviews in Medical Virology</i> , 2020, 30, e2108.	3.9	13
65	Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. <i>Supportive Care in Cancer</i> , 2020, 28, 6023-6034.	1.0	7
66	Levofloxacin prophylaxis in patients with myeloma. <i>Lancet Oncology</i> , The, 2020, 21, e67.	5.1	6
67	High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
68	Mold-active prophylaxis in acute leukemia: not enough of a good thing?. <i>Leukemia and Lymphoma</i> , 2019, 60, 2851-2853.	0.6	1
69	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 511-519.	1.0	2
70	<i>Mycobacterium abscessus</i> bloodstream infection: Unexpected catheter tunnel infection localized by PET/CT. <i>Transplant Infectious Disease</i> , 2019, 21, e13147.	0.7	5
71	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2151-2153.	2.0	22
72	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 487-492.	1.0	5

#	ARTICLE	IF	CITATIONS
73	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 493-509.	1.0	4
74	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 521-534.	1.0	2
75	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia â€“ lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma, 2019, 60, 3455-3460.	0.6	4
76	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
77	Microbiome transplantation and modulation of immune related adverse events. EClinicalMedicine, 2019, 8, 10-11.	3.2	7
78	Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program. Leukemia and Lymphoma, 2019, 60, 2373-2383.	0.6	11
79	Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression. Journal of Clinical Oncology, 2019, 37, 1139-1140.	0.8	14
80	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. Leukemia and Lymphoma, 2019, 60, 2471-2476.	0.6	7
81	Impact of a hospital-wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre. European Journal of Cancer Care, 2019, 28, e13018.	0.7	3
82	Azole antifungals and new targeted therapies for hematological malignancy. Current Opinion in Infectious Diseases, 2019, 32, 538-545.	1.3	49
83	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope. Critical Reviews in Microbiology, 2019, 45, 1-21.	2.7	106
84	High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 1572-1575.	0.6	19
85	Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. International Journal of Antimicrobial Agents, 2019, 53, 589-597.	1.1	79
86	The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1341-1343.e1.	2.0	25
87	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. Internal Medicine Journal, 2019, 49, 615-621.	0.5	6
88	Utilizing genomic analyses to investigate the first outbreak of van A vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility. Journal of Medical Microbiology, 2019, 68, 303-308.	0.7	14
89	The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3437-3437.	0.6	2
90	Management of fever and neutropenia in children with cancer: A survey of Australian and New Zealand practice. Journal of Paediatrics and Child Health, 2018, 54, 761-769.	0.4	20

#	ARTICLE	IF	CITATIONS
91	Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 748-756.	1.3	18
92	In vitro activity of the novel antifungal compound F901318 against Australian <i>Scedosporium</i> and <i>Lomentospora</i> fungi. <i>Medical Mycology</i> , 2018, 56, 1050-1054.	0.3	44
93	Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. <i>Blood Reviews</i> , 2018, 32, 499-507.	2.8	57
94	Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1490-1496.	2.0	29
95	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	1.7	125
96	Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. <i>Supportive Care in Cancer</i> , 2018, 26, 997-1003.	1.0	18
97	External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 329-335.	1.1	15
98	The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy306.	0.4	57
99	Whole Genome Sequencing of Australian <i>Candida glabrata</i> Isolates Reveals Genetic Diversity and Novel Sequence Types. <i>Frontiers in Microbiology</i> , 2018, 9, 2946.	1.5	31
100	Antifungal stewardship: developments in the field. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 490-498.	1.3	25
101	Invasive fungal disease and cytomegalovirus infection: is there an association?. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 481-489.	1.3	47
102	How antibiotic allergy labels may be harming our most vulnerable patients. <i>Medical Journal of Australia</i> , 2018, 208, 469-470.	0.8	15
103	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	1.3	186
104	Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3209-3211.	1.3	6
105	Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. <i>BMJ Open Quality</i> , 2018, 7, e000355.	0.4	41
106	Changing epidemiology of candidaemia in Australia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw422.	1.3	89
107	Risks factors and outcomes of <i>Clostridium difficile</i> infection in patients with cancer: a matched case-control study. <i>Supportive Care in Cancer</i> , 2017, 25, 1923-1930.	1.0	22
108	New developments and directions in the clinical application of the echinocandins. <i>Archives of Toxicology</i> , 2017, 91, 1613-1621.	1.9	41



#	ARTICLE	IF	CITATIONS
109	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1684-1694.	1.9	61
110	Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: a case series. <i>Journal of Pharmacy Practice and Research</i> , 2017, 47, 228-235.	0.5	1
111	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. <i>Clinical Infectious Diseases</i> , 2017, 65, 166-174.	2.9	106
112	Predicting Infectious Complications in Children with Cancer: an external validation study. <i>British Journal of Cancer</i> , 2017, 117, 171-178.	2.9	31
113	Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 493-502.	2.0	15
114	Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2017, 58, 2379-2386.	0.6	21
115	Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2089-2092.	1.3	5
116	Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers. <i>Vaccine</i> , 2017, 35, 2558-2568.	1.7	30
117	Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. <i>Supportive Care in Cancer</i> , 2017, 25, 3289-3290.	1.0	1
118	What, where and why: exploring fluorodeoxyglucose-PET's ability to localise and differentiate infection from cancer. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 552-564.	1.3	12
119	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1532-1542.	2.0	60
120	Influenza vaccination of ambulatory patients with cancer at a tertiary healthcare facility: Putting guidelines into practice. <i>Infection, Disease and Health</i> , 2017, 22, 150-152.	0.5	1
121	Ibrutinib may impair serological responses to influenza vaccination. <i>Haematologica</i> , 2017, 102, e397-e399.	1.7	79
122	Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e344-e356.	4.6	124
123	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1961-1967.	2.0	56
124	Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical Laboratories. <i>Current Fungal Infection Reports</i> , 2017, 11, 124-133.	0.9	3
125	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. <i>Mycoses</i> , 2017, 60, 79-88.	1.8	7
126	Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. <i>European Journal of Haematology</i> , 2017, 98, 149-153.	1.1	26



#	ARTICLE	IF	CITATIONS
127	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. <i>Frontiers in Immunology</i> , 2017, 8, 1247.	2.2	10
128	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1506.	2.2	13
129	Toward Electronic Surveillance of Invasive Mold Diseases in Hematology-Oncology Patients: An Expert System Combining Natural Language Processing of Chest Computed Tomography Reports, Microbiology, and Antifungal Drug Data. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-10.	1.0	14
130	Cart before the horse: use of <i>Aspergillus</i> PCR to increase the diagnostic yield from BAL in hematological patients at risk of invasive aspergillosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 2773-2776.	0.6	3
131	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw153.	0.4	57
132	Invasive fungal infections in ALL: a new "growth" area. <i>Leukemia and Lymphoma</i> , 2016, 57, 1985-1987.	0.6	1
133	Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 67, 21-37.	1.3	49
134	The epidemiology of <i>Clostridium difficile</i> infection in patients with cancer. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1077-1085.	2.0	19
135	Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1165-1177.	2.0	7
136	Yeast Infections After Haematopoietic Stem Cell Transplantation. , 2016, , 677-691.		0
137	Antifungal susceptibilities of non- <i>Aspergillus</i> filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 453-458.	1.1	24
138	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3540-3547.	1.3	19
139	Aseptic Technique for Accessing Central Venous Catheters: Applying a Standardised tool to Audit "Scrub the Hub" Practices. <i>Journal of Vascular Access</i> , 2016, 17, 269-272.	0.5	7
140	Mucormycosis in Australia: contemporary epidemiology and outcomes. <i>Clinical Microbiology and Infection</i> , 2016, 22, 775-781.	2.8	83
141	Emerging infections caused by non- <i>Aspergillus</i> filamentous fungi. <i>Clinical Microbiology and Infection</i> , 2016, 22, 670-680.	2.8	78
142	Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1719-1722.	0.6	7
143	Isavuconazole: a role for the newest broad-spectrum triazole. <i>Lancet, The</i> , 2016, 387, 726-728.	6.3	18
144	Antimicrobial allergy "labels" drive inappropriate antimicrobial prescribing: lessons for stewardship. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1715-1722.	1.3	95

#	ARTICLE	IF	CITATIONS
145	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 497-505.	1.3	30
146	Epidemiology of invasive fungal disease in lymphoproliferative disorders. <i>Haematologica</i> , 2015, 100, e462-e466.	1.7	30
147	The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 23.	1.5	52
148	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. <i>British Journal of Haematology</i> , 2015, 171, 100-108.	1.2	94
149	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. <i>Supportive Care in Cancer</i> , 2015, 23, 1901-1906.	1.0	30
150	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. <i>Haematologica</i> , 2015, 100, e28-e31.	1.7	62
151	Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. <i>Clinical Therapeutics</i> , 2015, 37, 1317-1328.e2.	1.1	26
152	The prevention and management of infections due to multidrug resistant organisms in haematology patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 195-207.	1.1	41
153	Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibiotics. <i>Leukemia and Lymphoma</i> , 2015, 56, 3243-3245.	0.6	2
154	<i>Candida glabrata</i> fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3442-3444.	0.6	6
155	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , 2015, 61, 1293-1303.	2.9	157
156	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	2.0	376
157	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. <i>Leukemia and Lymphoma</i> , 2015, 56, 157-162.	0.6	11
158	Automatic detection of patients with invasive fungal disease from free-text computed tomography (CT) scans. <i>Journal of Biomedical Informatics</i> , 2015, 53, 251-260.	2.5	23
159	Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. <i>BMC Infectious Diseases</i> , 2015, 15, 128.	1.3	46
160	Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis. <i>Critical Reviews in Microbiology</i> , 2015, 41, 124-134.	2.7	100
161	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1325-1336.	2.0	19
162	A different kind of allogeneic transplant: successful fecal microbiota transplant for recurrent and refractory <i>Clostridium difficile</i> infection in a patient with relapsed aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 512-514.	0.6	14

#	ARTICLE	IF	CITATIONS
163	Multi-triazole-resistant <i>Aspergillus fumigatus</i> infections in Australia. <i>Mycoses</i> , 2015, 58, 350-355.	1.8	89
164	An Approach to a Pulmonary Infiltrate in Solid Organ Transplant Recipients. <i>Current Fungal Infection Reports</i> , 2015, 9, 144-154.	0.9	2
165	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , 2015, 60, 713-720.	2.9	75
166	Clinical and Translational Mycology on the southern shores: perspective from the Australia and New Zealand Mycoses Interest Group. <i>Microbiology Australia</i> , 2015, 36, 57.	0.1	0
167	Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. <i>Medical Journal of Australia</i> , 2014, 201, 543-544.	0.8	15
168	Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1298-1314.	0.5	37
169	Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1315-1332.	0.5	61
170	More than a feeling: new approach required for assessing immunosuppression. <i>Leukemia and Lymphoma</i> , 2014, 55, 975-976.	0.6	0
171	Are they protected? Immunity to vaccine-preventable diseases in healthcare workers at an Australian hospital. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 83-86.	0.8	10
172	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1283-1297.	0.5	108
173	Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1267-1276.	0.5	19
174	Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1389-1397.	0.5	30
175	Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 207-214.	1.1	25
176	Clinical utility of <i>Aspergillus galactomannan</i> and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 322-327.	0.8	54
177	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. <i>Blood Reviews</i> , 2014, 28, 75-86.	2.8	52
178	Molecular diagnosis of <i>Pneumocystis jirovecii</i> in patients with malignancy: Clinical significance of quantitative polymerase chain reaction. <i>Medical Mycology</i> , 2014, 52, 427-432.	0.3	10
179	Protothecosis in hematopoietic stem cell transplantation: case report and review of previous cases. <i>Transplant Infectious Disease</i> , 2014, 16, 490-495.	0.7	15
180	Facilitating Surveillance of Pulmonary Invasive Mold Diseases in Patients with Haematological Malignancies by Screening Computed Tomography Reports Using Natural Language Processing. <i>PLoS ONE</i> , 2014, 9, e107797.	1.1	15

#	ARTICLE	IF	CITATIONS
181	Invasive Fungal Infections: A Continuing Challenge Report from the 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 24-27 July 2012. <i>Current Fungal Infection Reports</i> , 2013, 7, 83-88.	0.9	0
182	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 519-528.	4.6	198
183	Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient. <i>Transplant Infectious Disease</i> , 2013, 15, E14-9.	0.7	18
184	Fluoroquinolone prophylaxis: worth the cost?. <i>Leukemia and Lymphoma</i> , 2013, 54, 677-678.	0.6	7
185	Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC). <i>Mycoses</i> , 2013, 56, 532-542.	1.8	10
186	Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 227-235.	0.7	7
187	Cryptococcosis, lymphoproliferative disorders and modern day chemotherapy regimens. <i>Leukemia and Lymphoma</i> , 2013, 54, 449-450.	0.6	8
188	Relationship between Trough Plasma and Epithelial Lining Fluid Concentrations of Voriconazole in Lung Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4581-4583.	1.4	14
189	Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1669-1678.	1.3	19
190	Outpatient Therapy for Fever and Neutropenia Is Safe but Implementation Is the Key. <i>Journal of Clinical Oncology</i> , 2013, 31, 1128-1129.	0.8	8
191	Antifungal Therapy and Management of Complications of Cryptococcosis due to <i>Cryptococcus gattii</i> . <i>Clinical Infectious Diseases</i> , 2013, 57, 543-551.	2.9	106
192	Late-onset pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. <i>European Journal of Haematology</i> , 2013, 91, 157-163.	1.1	23
193	Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2274-2282.	1.3	13
194	The case for antifungal stewardship. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 107-115.	1.3	115
195	Making sense of posaconazole therapeutic drug monitoring. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 605-611.	1.3	31
196	<i>Staphylococcus aureus</i> meningitis: barriers to treatment. <i>Leukemia and Lymphoma</i> , 2012, 53, 1443-1444.	0.6	3
197	Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. <i>Haematologica</i> , 2012, 97, 459-463.	1.7	99
198	Clinical and Economic Burden of Emergency Department Presentations for Neutropenia Following Outpatient Chemotherapy for Cancer in Victoria, Australia. <i>Oncologist</i> , 2012, 17, 998-1004.	1.9	14

#	ARTICLE	IF	CITATIONS
199	Opportunistic fungal infections in the Asia-Pacific region. <i>Medical Mycology</i> , 2012, 50, 18-25.	0.3	54
200	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1889-1895.	0.6	23
201	Clinical Manifestations of <i>Cryptococcus gattii</i> Infection: Determinants of Neurological Sequelae and Death. <i>Clinical Infectious Diseases</i> , 2012, 55, 789-798.	2.9	171
202	Influenza vaccination uptake in an Australian hospital: time to make it mandatory for health care workers?. <i>Medical Journal of Australia</i> , 2012, 197, 552-552.	0.8	9
203	Public disclosure of health care-associated infections in Australia: quality improvement or parody?. <i>Medical Journal of Australia</i> , 2012, 197, 29-29.	0.8	7
204	Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins. <i>Current Fungal Infection Reports</i> , 2012, 6, 95-106.	0.9	0
205	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1348-1355.	3.3	31
206	Fluoroquinolone prophylaxis: a word of caution. <i>Leukemia and Lymphoma</i> , 2011, 52, 5-6.	0.6	14
207	Echinocandin Antifungal Drugs in Fungal Infections. <i>Drugs</i> , 2011, 71, 11-41.	4.9	324
208	Endemic fungal infections in the Asia-Pacific region. <i>Medical Mycology</i> , 2011, 49, 337-344.	0.3	77
209	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. <i>Internal Medicine Journal</i> , 2011, 41, 75-81.	0.5	27
210	Use of empiric antimicrobial therapy in neutropenic fever. <i>Internal Medicine Journal</i> , 2011, 41, 90-101.	0.5	67
211	Use of antibacterial prophylaxis for patients with neutropenia. <i>Internal Medicine Journal</i> , 2011, 41, 102-109.	0.5	45
212	Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. <i>British Journal of Haematology</i> , 2011, 153, 681-697.	1.2	40
213	Antifungal Prophylaxis in Lung Transplantation—A World-wide Survey. <i>American Journal of Transplantation</i> , 2011, 11, 361-366.	2.6	126
214	Pneumonia and Lung Infections due to Emerging and Unusual Fungal Pathogens. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 703-716.	0.8	27
215	Anaerobes: not to be forgotten in neutropenic fever. <i>Leukemia and Lymphoma</i> , 2011, 52, 948-949.	0.6	0
216	Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1906-1915.	1.3	29

#	ARTICLE	IF	CITATIONS
217	Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1953-1960.	1.4	75
218	<i>Stenotrophomonas maltophilia</i> : emerging disease patterns and challenges for treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 471-488.	2.0	85
219	Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 179-193.	0.6	16
220	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. <i>Australian Health Review</i> , 2011, 35, 491.	0.5	20
221	Editorial comment. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 545.	1.3	0
222	Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. <i>Medical Journal of Australia</i> , 2010, 192, 84-86.	0.8	82
223	Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1052-1061.	1.3	30
224	Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1042-1051.	1.3	148
225	Pharmacoeconomics of voriconazole in the management of invasive fungal infections. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 623-636.	0.7	7
226	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. <i>Emerging Infectious Diseases</i> , 2010, 16, 1068-1075.	2.0	108
227	Toxoplasmosis and allogeneic stem cell transplantation: can we do better?. <i>Leukemia and Lymphoma</i> , 2010, 51, 1395-1396.	0.6	4
228	Isavuconazole. , 2010, , 1882-1886.		0
229	Albaconazole. , 2010, , 1877-1881.		0
230	Ravuconazole. , 2010, , 1871-1876.		0
231	Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients. <i>Pediatrics</i> , 2009, 123, 1360-1368.	1.0	171
232	Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. <i>Supportive Care in Cancer</i> , 2009, 17, 811-818.	1.0	76
233	Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation. <i>Current Infectious Disease Reports</i> , 2009, 11, 420-426.	1.3	5
234	Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. <i>Transplant Infectious Disease</i> , 2009, 11, 122-127.	0.7	55



#	ARTICLE	IF	CITATIONS
235	Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of <i>Scedosporium aurantiacum</i> infection. <i>Clinical Microbiology and Infection</i> , 2009, 15, 689-693.	2.8	102
236	Candidaemia with uncommon <i>Candida</i> species: predisposing factors, outcome, antifungal susceptibility, and implications for management. <i>Clinical Microbiology and Infection</i> , 2009, 15, 662-669.	2.8	79
237	Bloodstream infections in haematology: Risks and new challenges for prevention. <i>Blood Reviews</i> , 2009, 23, 113-122.	2.8	34
238	Determinants of mortality in non-neutropenic ICU patients with candidaemia. <i>Critical Care</i> , 2009, 13, R115.	2.5	79
239	Utility of a proposed CSP typing nomenclature for Australian <i>Aspergillus fumigatus</i> isolates: Identification of additional CSP types and suggested modifications. <i>Journal of Microbiological Methods</i> , 2009, 78, 223-226.	0.7	15
240	Surgical Management of Invasive Pulmonary Fungal Infection in Hematology Patients. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1532-1538.	0.7	19
241	Molecular Epidemiology of Invasive Aspergillosis: Lessons Learned from an Outbreak Investigation in an Australian Hematology Unit. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1223-1226.	1.0	14
242	Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. <i>Internal Medicine Journal</i> , 2008, 38, 468-476.	0.5	31
243	Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. <i>Internal Medicine Journal</i> , 2008, 38, 521-537.	0.5	51
244	Preventing invasive fungal infection during hospital building works. <i>Internal Medicine Journal</i> , 2008, 38, 538-541.	0.5	26
245	Virulence determinants in vancomycin-resistant <i>Enterococcus faecium</i> vanB: clonal distribution, prevalence and significance of <i>esp</i> and <i>hyl</i> in Australian patients with haematological disorders. <i>Journal of Hospital Infection</i> , 2008, 68, 137-144.	1.4	27
246	Surveillance for Catheter-Associated Bloodstream Infection in Hematology Units: Quantifying the Characteristics of a Practical Case Definition. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 358-360.	1.0	15
247	Reply to Graham and Olver. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 986-987.	1.0	0
248	Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1743-1750.	1.4	274
249	Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans <i>Candida</i> spp.. <i>Critical Care Medicine</i> , 2008, 36, 2034-2039.	0.4	134
250	Molecular Typing of Australian <i>Scedosporium</i> Isolates Showing Genetic Variability and Numerous <i>S. aurantiacum</i> . <i>Emerging Infectious Diseases</i> , 2008, 14, 282-290.	2.0	74
251	Infection with <i>Scedosporium apiospermum</i> and <i>S. prolificans</i> , Australia. <i>Emerging Infectious Diseases</i> , 2007, 13, 1170-1177.	2.0	78
252	Catheter-related bloodstream infections in hematology. <i>Cancer</i> , 2007, 109, 1215-1226.	2.0	40



#	ARTICLE	IF	CITATIONS
253	Breakthrough <i>Scedosporium prolificans</i> infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2007, 9, 241-243.	0.7	43
254	Vancomycin-resistant <i>Enterococcus faecium</i> infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. <i>European Journal of Haematology</i> , 2007, 79, 226-233.	1.1	77
255	<i>Mycobacterium tuberculosis</i> infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. <i>Tuberculosis</i> , 2007, 87, 459-463.	0.8	67
256	Emerging opportunistic yeast infections in haematology patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1736-1737.	0.6	3
257	Active Surveillance of Candidemia, Australia. <i>Emerging Infectious Diseases</i> , 2006, 12, 1508-1516.	2.0	151
258	Miliary tuberculosis in a Caucasian male transplant recipient and the role of intravenous immunoglobulin as an immunosuppressive sparing agent (Case Report). <i>Nephrology</i> , 2006, 11, 156-158.	0.7	6
259	Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. <i>British Journal of Haematology</i> , 2006, 132, 3-12.	1.2	178
260	Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy. <i>Medical Mycology</i> , 2006, 44, 333-348.	0.3	7
261	An analysis of the utilisation of chemoprophylaxis against <i>Pneumocystis jirovecii</i> pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. <i>British Journal of Cancer</i> , 2005, 92, 867-872.	2.9	70
262	Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. <i>Haematologica</i> , 2005, 90, 1672-9.	1.7	53
263	Fatal Anaerobic Bacteremia after Hematopoietic Stem Cell Transplant. <i>Leukemia and Lymphoma</i> , 2004, 45, 143-145.	0.6	2
264	Guidelines for the use of antifungal agents in the treatment of invasive <i>Candida</i> and mould infections. <i>Internal Medicine Journal</i> , 2004, 34, 192-200.	0.5	46
265	Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 115-121.	1.3	75
266	Burden of hospitalization of patients with <i>Candida</i> and <i>Aspergillus</i> infections in Australia. <i>International Journal of Infectious Diseases</i> , 2004, 8, 111-120.	1.5	47
267	Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting. <i>Blood</i> , 2004, 104, 3837-3837.	0.6	1
268	Progressive Multifocal Leukoencephalopathy Complicating Waldenström's Macroglobulinaemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1819-1821.	0.6	18
269	<i>Legionella pneumophila</i> mip gene sequencing to investigate a cluster of pneumonia cases. <i>Pathology</i> , 2003, 35, 65-69.	0.3	1
270	<i>Legionella pneumophila</i> mip gene sequencing to investigate a cluster of pneumonia cases. <i>Pathology</i> , 2003, 35, 65-69.	0.3	2

#	ARTICLE	IF	CITATIONS
271	The epidemiology of candidaemia and mould infections in Australia. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 3-6.	1.3	53
272	Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphopenia. <i>Leukemia and Lymphoma</i> , 2001, 41, 421-423.	0.6	33
273	Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF. <i>Leukemia and Lymphoma</i> , 2001, 42, 1393-1399.	0.6	35
274	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	0.6	480
275	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	0.6	5
276	Efficacy and Safety of Fluconazole Prophylaxis for Fungal Infections after Marrow Transplantation--A Prospective, Randomized, Double-Blind Study. <i>Journal of Infectious Diseases</i> , 1995, 171, 1545-1552.	1.9	800
277	PREDICTION OF CYTOMEGALOVIRUS PNEUMONIA AFTER MARROW TRANSPLANTATION FROM CELLULAR CHARACTERISTICS AND CYTOMEGALOVIRUS CULTURE OF BRONCHOALVEOLAR LAVAGE FLUID. <i>Transplantation</i> , 1994, 58, 915-919.	0.5	18
278	Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 1360-1363.	1.4	43
279	Oral dapsone versus nebulized pentamidine for <i>Pneumocystis carinii</i> pneumonia prophylaxis. <i>Aids</i> , 1992, 6, 1169-1174.	1.0	36